Recent events
Recent events tied to this brand in public sources.
Back to profile7 entries
2022
Bio-Rad launches anti-daratumumab antibodies
Bio-Rad announced the launch of a range of anti-daratumumab antibodies that inhibit daratumumab from binding to its target, CD38. The article states that the antibodies are suitable for bioanalysis and drug monitoring of daratumumab and its biosimilars.
2021
Bio-Rad announces Simon May appointment to lead Life Science Group
Bio-Rad announced Simon May's appointment as Executive Vice President and President of its Life Science Group, effective January 4, 2022. He is to succeed Annette Tumolo, who will retire from the role.
2021
Seegene and Bio-Rad sign U.S. diagnostic-products partnership
Seegene said it signed a partnership with Bio-Rad for clinical development and commercialization of infectious-disease molecular diagnostic products for the U.S. market, subject to clinical development and FDA approval.
2021
Bio-Rad introduces three StarBright Dyes
Bio-Rad introduced StarBright Violet 570, 670 and 710 Dyes for flow cytometry applications.
2020
Bio-Rad launches PIF Supplement
Bio-Rad announced the launch of its PIF Supplement for enriching Enterobacteriaceae, including Salmonella and Cronobacter, in powdered infant formula, dairy ingredients and cereal.
2020
Bio-Rad launches SARS CoV-2 Standard
Bio-Rad launched a SARS CoV-2 Standard through its Exact Diagnostics product line to support laboratory validation of COVID-19 testing assays.
2020
Bio-Rad launches SARS CoV-2 Standard
Bio-Rad announced that it launched the SARS CoV-2 Standard through its Exact Diagnostics product line to support laboratory validation of COVID-19 testing assays.